Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8174MR)

This product GTTS-WQ8174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8174MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14198MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ4813MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ4491MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ6954MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5363MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ11047MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ2815MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ2882MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW